This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Belsomra

Merck & Co., Inc.

Drug Names(s): MK-4305, MK4305, Suvorexant

Description: MK-4305 is a dual orexin receptor antagonist, inhibiting the actions of the neuropeptides orexin A and orexin B, which bind with the OX1R and OX2R receptors (OX1R binds orexin A, and OX2R binds both). These neuropeptides are produced by neurons in the hypothalamus, and play a key role in regulation of the brain's sleep-wake process. Orexin antagonists are thought to block the stimulation of the brain's arousal system.


Belsomra News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug